Core Insights - Pacira BioSciences Inc. (NASDAQ:PCRX) is recognized as one of the top small-cap drug manufacturing stocks favored by hedge funds [1] - The company presented data at the AAOS 2026 Annual Meeting, showcasing Exparel's benefits in pain management, including improved outcomes, reduced opioid use, and shorter hospital stays compared to standard treatments [1] - Iovera demonstrated longer-lasting pain relief and functional improvement, with benefits lasting up to 12 months, reinforcing the company's position in post-surgical pain management [3] Legislative Impact - A survey conducted by the Voices for Non-Opioid Choices coalition revealed the initial effects of the NOPAIN Act, which was implemented on January 1, 2025 [4][5] - 85% of facility representatives surveyed were aware of the NOPAIN Act, and over half of the facilities have made changes to increase the use of non-opioid options [5] - More than 80% of those surveyed reported a reduction in opioid prescribing for immediate post-surgery and discharge due to the legislation [5] Company Focus - Pacira BioSciences is dedicated to developing and marketing non-opioid pain management and regenerative health solutions, with a portfolio that includes EXPAREL, ZILRETTA, PCRX-201, NOCITA, and a handheld cryoanalgesia device [6]

Summary of Pacira BioSciences FY Conference Call Company Overview - **Company**: Pacira BioSciences (NasdaqGS:PCRX) - **Key Products**: EXPAREL, ZILRETTA, iovera - **Strategic Plan**: Five by Thirty strategy aiming for 3 million patients by 2030, double-digit top-line growth, 5-point margin expansion, 5 pipeline products, and 5 partnerships [2][3] Core Insights and Arguments - **NOPAIN Act Implementation**: - Launched in January 2025, providing reimbursement for EXPAREL outside of bundled payments at ASP + 6% for Medicare patients [4][19] - Expanded coverage to commercial payers, achieving up to ASP + 29% [4][20] - 102 million lives covered outside the bundle by year-end [4] - Positive impact on opioid utilization expected due to the NOPAIN Act [20][22] - **Volume Growth**: - EXPAREL experienced over 6% volume growth in 2025, up from 3% the previous year [15] - Anticipated steady increase in volume and revenue convergence in the second half of 2026 as GPO contracts are fully realized [17][27] - **Financial Guidance for 2026**: - Total company revenue expected to grow 3%-6%, with EXPAREL projected to grow 4%-8% [23] - Emphasis on execution and expanding payer coverage to achieve higher revenue targets [27] - **Partnerships**: - Significant agreements with Johnson & Johnson MedTech to enhance ZILRETTA's market reach and with LG Chem for EXPAREL and ZILRETTA in Asia Pacific [5][50] - Focus on building partnerships in Europe and Latin America to expand market presence [50] Pipeline Developments - **PCRX-201**: - Potential game-changing gene therapy for osteoarthritis, with promising phase 1 results and phase 2 part A results expected by year-end [60][66] - RMAT designation received to accelerate development [65] - **ZILRETTA and iovera**: - Anticipated growth driven by the J&J partnership and dedicated sales forces for each product [39][25] - Upcoming data events for ZILRETTA and iovera expected to provide further insights into their market potential [40] Additional Important Points - **Operational Efficiency**: - Improved margin from 76% due to better inventory management and reduced waste [43] - Continuous improvement in processes expected to support margin expansion [45] - **Market Awareness**: - High awareness of NOPAIN among healthcare professionals, with about half taking action to manage patients differently [21] - Ongoing claims analysis to support the positive impact of NOPAIN on patient outcomes and healthcare costs [22] - **Financial Position**: - Strong financial health with low leverage and capacity for accretive deals [77] - Focus on disciplined capital allocation to enhance growth [76] This summary encapsulates the key points discussed during the Pacira BioSciences FY Conference Call, highlighting the company's strategic initiatives, financial outlook, and product pipeline developments.

Core Insights - The fourth-quarter 2025 reporting cycle for the Medical sector is commencing, with major firms expected to release earnings results in the coming weeks, primarily in the pharma/biotech and medical device segments [1] - Johnson & Johnson's strong performance has set a positive tone, while Roche faced challenges due to unfavorable foreign-exchange impacts, particularly from a weak U.S. dollar [1] - Sanofi reported mixed results, beating earnings estimates but slightly missing sales expectations [1] Earnings Trends - As of January 28, 11.7% of Medical sector companies, representing 26% of the sector's market capitalization, have reported quarterly earnings, with 42.9% beating both earnings and revenue estimates [2] - Year-over-year earnings decreased by 15.5%, while revenues increased by 10.3% [2] - Overall, fourth-quarter earnings for the Medical sector are expected to decrease by 2.4%, while sales are projected to rise by 8.7% compared to the previous year [3] Company Highlights - **Zoetis (ZTS)**: Expected to report earnings on February 12, with a consensus estimate of $1.40 per share and revenues of $2.37 billion. The company has an Earnings ESP of +0.84% and a Zacks Rank of 3. Recent performance has been driven by strong demand for companion animal products, although sales of certain monoclonal antibody products may have declined [7][8] - **Pacira BioSciences (PCRX)**: Anticipated to report earnings soon, with a consensus estimate of 85 cents per share and revenues of $196.99 million. The company has an Earnings ESP of +7.38% and a Zacks Rank of 2. Revenue growth is expected from its pain-management product, Exparel, and other products [9][10] - **Apellis Pharmaceuticals (APLS)**: Expected to report earnings soon, with a consensus estimate of a loss of 41 cents per share and revenues of $194.37 million. The company has an Earnings ESP of +4.52% and a Zacks Rank of 3. Revenue growth is likely driven by its geographic atrophy drug, Syfovre [11][12] - **Acadia Pharmaceuticals (ACAD)**: Set to report earnings soon, with a consensus estimate of 12 cents per share and revenues of $292.64 million. The company has an Earnings ESP of +14.92% and a Zacks Rank of 3. Revenue growth is expected from its lead drug, Nuplazid, and its second product, Daybue [13][14] - **Denali Therapeutics (DNLI)**: Expected to report a loss of 75 cents per share and revenues of $18.47 million. The company has an Earnings ESP of +6.11% and a Zacks Rank of 3. Revenue expectations are based on collaboration revenues, with updates on pipeline programs anticipated [15][16]

Core Insights - Pacira BioSciences (PCRX) reported preliminary, unaudited total revenues of $196.9 million for Q4 2025, missing the Zacks Consensus Estimate of $199 million, leading to a 9.6% decline in stock price [1][5] Group 1: Product Revenues - Exparel's net product sales reached $155.8 million in Q4 2025, a 5% increase from the previous year, slightly exceeding the Zacks Consensus Estimate of $155 million [3][5] - Zilretta's net product sales were reported at $33 million, remaining flat year over year and missing the Zacks Consensus Estimate of $34.4 million [6][7] - Iovera's net product sales amounted to $7 million, an 8% increase from the year-ago quarter, but fell short of the Zacks Consensus Estimate of $7.3 million [8] Group 2: Annual Performance - For the full year 2025, Pacira BioSciences reported total revenues of $726.4 million, a 4% increase year over year, but below the Zacks Consensus Estimate of $728.8 million [9]

Core Insights - Pacira Biosciences has joined the PROBE Consortium to enhance osteoarthritis research and patient care globally, leveraging data from over 70 million individuals [1][3] - The initiative aims to address significant unmet needs in osteoarthritis treatment, particularly due to a lack of innovation since the introduction of ZILRETTA [2][3] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [4] - ZILRETTA is the first and only extended-release intra-articular therapy approved for osteoarthritis knee pain, providing pain relief for up to 16 weeks [5] PROBE Consortium Objectives - The PROBE initiative includes 38 partners from various sectors, aiming to transform osteoarthritis diagnosis and treatment through improved data analysis and trial designs [3][7] - Key strategies include creating a regulation-compliant database network, utilizing AI for disease progression predictions, and developing novel trial endpoints [7]

Financial Data and Key Metrics Changes - Year-over-year revenues increased by 6%, driven by strong performance from Exparel and iovera [4] - Third-quarter Exparel sales rose to $139.9 million from $132.0 million in 2024, with a volume growth of 9% [21] - Non-GAAP gross margin improved to 82% from 78% year-over-year, benefiting from manufacturing efficiencies [22] - Adjusted EBITDA for the third quarter was $49.4 million [22] Business Line Data and Key Metrics Changes - Exparel demand saw a year-over-year volume increase of approximately 9%, marking the highest quarterly growth in over three years [4] - ZILRETTA sales increased to $29.0 million from $28.4 million in 2024 [21] - Iovera sales grew to $6.5 million from $5.7 million in 2024 [21] Market Data and Key Metrics Changes - Approximately 60 million commercial lives now have access to Exparel through separate reimbursement mechanisms, with a total covered population nearing 90 million across commercial and government payers [15] - Strong adoption of Exparel in ambulatory surgery centers, with volumes up more than 25% year-over-year [19] Company Strategy and Development Direction - The company is focused on its 5x30 growth strategy, which aims for a five-year double-digit compound annual growth rate (CAGR) for revenue [14] - The in-licensing of AMT 143 aligns with the company's strategy to expand its clinical pipeline and enhance its product offerings [5] - The company is prioritizing complementary mid to late-stage opportunities in its pipeline, particularly in musculoskeletal pain [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Exparel, anticipating that volume growth will converge with revenue growth over time [21] - The company expects to see significant earnings driven by improving sales and enhanced gross margins [25] - Management remains optimistic about the potential of PCRX 201 to revolutionize osteoarthritis treatment [8] Other Important Information - The company executed an additional $50 million in share repurchases during the third quarter [23] - The company has a strong balance sheet with cash and investments of approximately $246 million [23] Q&A Session Summary Question: Impact of GPO on volume growth and selling days - Management noted strong uptake from the GPO signed in June, which contributed to volume growth [30] - There was no significant impact from the number of selling days in the quarter [33] Question: Rationale behind AMT 143 program and trial design - The company sees a market need for a product with longer durability and ease of use, complementary to Exparel [35] - IP protection for AMT 143 extends to 2042, with plans to expand upon that [38] Question: Awareness of Exparel in larger hospitals and market growth for elective procedures - Growth has been faster in smaller hospitals and ASCs, with larger institutions taking more time due to more decision-makers [43] - Modest improvements in elective procedures were noted in the third quarter, with expectations for more in the fourth quarter [49] Question: Early indicators for ZORVOLTA and gross margin expectations - The dedicated ZORVOLTA sales force is expected to drive momentum in the fourth quarter and significant progress in 2026 [52] - Gross margins are expected to improve next year, with a long-term goal of a 5% improvement over 2024 levels [56]

Core Insights - Pacira BioSciences, Inc. is presenting real-world evidence on the clinical effectiveness and economic benefits of EXPAREL at the AMCP Nexus 2025 Annual Meeting [1][3] - The company aims to advance understanding of postsurgical pain management and reduce reliance on opioids through multimodal pain pathways [3] Company Overview - Pacira specializes in innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and iovera [5] - EXPAREL is a long-acting local analgesic approved for various postsurgical pain management applications [5][6] - The company is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [5] Research Presentations - The AMCP Nexus 2025 will feature presentations on the impact of liposomal bupivacaine on healthcare resource utilization and costs in total knee arthroplasty [4] - Additional presentations will cover outcomes related to intraoperative liposomal bupivacaine and its effects on opioid use and functional outcomes [7] Product Details - EXPAREL utilizes multivesicular liposome technology to deliver bupivacaine over time, achieving significant reductions in cumulative pain scores and opioid consumption [8] - The product is indicated for postsurgical local and regional analgesia in patients aged 6 years and older [6]

Core Insights - Pacira reported $181.1 million in revenue for Q2 2025, a year-over-year increase of 1.7%, with an EPS of $0.74 compared to $0.89 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $184.23 million, resulting in a surprise of -1.7%, while the EPS exceeded the consensus estimate of $0.72 by +2.78% [1] Revenue Breakdown - Net product sales for iovera were $5.59 million, below the average estimate of $6.12 million, reflecting a year-over-year decline of -1.5% [4] - Net product sales for ZILRETTA reached $31.33 million, slightly above the estimated $31.17 million, marking a +2% increase year-over-year [4] - Net product sales for EXPAREL totaled $142.92 million, compared to the average estimate of $145.83 million, showing a year-over-year growth of +4.4% [4] - Total net product sales amounted to $180.35 million, below the average estimate of $184.5 million, with a year-over-year increase of +2.3% [4] - Net product sales for Bupivacaine liposome injectable suspension were $0.51 million, significantly lower than the estimated $1.64 million, indicating a year-over-year decline of -83.9% [4] - Royalty revenue was reported at $0.75 million, below the estimated $1.42 million, representing a -54% change compared to the previous year [4] Stock Performance - Pacira's shares have returned -1.2% over the past month, while the Zacks S&P 500 composite has increased by +1% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Financial Data and Key Metrics Changes - The company reported second quarter EXPAREL sales increased to $142.9 million, up from $136.9 million in 2024, reflecting a 4% sales growth driven by a 6% volume increase [28] - Non-GAAP gross margin improved to 82% from 76% year-over-year, benefiting from improved costs and efficiencies [29] - Adjusted EBITDA for the second quarter was $54.3 million, indicating strong operational performance [31] - Full year revenue guidance was narrowed to $730 million to $750 million, with an increase in non-GAAP gross margin guidance to 78% to 80% from the previous range of 76% to 78% [34] Business Line Data and Key Metrics Changes - EXPAREL achieved 6% year-over-year volume growth, the highest in eight quarters, while ZILRETTA sales increased to $31.3 million from $30.7 million in 2024 [7][28] - Ioverao sales were $5.6 million, slightly down from $5.7 million in 2024 [28] - The company executed $50 million in share repurchases, retiring approximately 2 million shares of common stock [33] Market Data and Key Metrics Changes - The company estimates over 40 million commercial lives now have access to EXPAREL, with a target of reaching 60 million by year-end [20] - The company aims to cover nearly 100 million lives across both commercial and government payers by the end of the year [21] Company Strategy and Development Direction - The company is focused on its "five by thirty" strategy, which includes growing its commercial business and advancing an innovative pipeline [6] - A new partnership with Johnson & Johnson MedTech for ZILRETTA is expected to significantly expand reach and patient access [11] - The company is advancing its pipeline with a focus on musculoskeletal pain and adjacent markets, with ongoing registrational studies for ZILRETTA [13][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving sustainable earnings growth driven by improving sales and enhanced gross margins [35] - The company is optimistic about the impact of new CMS reimbursement policies on EXPAREL's market opportunity [8] - Management highlighted the importance of expanding commercial coverage and the positive momentum in outpatient settings [24] Other Important Information - The company has secured a favorable reexamination of its patent, which is expected to strengthen its intellectual property position [9] - The company is focused on disciplined capital allocation, prioritizing growth in its best-in-class business and returning capital to shareholders [33] Q&A Session Summary Question: Commentary on the new partnership with J&J MedTech for ZILRETTA - Management noted that the new partnership is under different circumstances compared to the previous co-promotion with EXPAREL, and it is expected to enhance market access significantly [42] Question: Expectations for impact to gross to net from the third GPO - Management indicated a low single-digit impact on gross to net, with a reasonable modeling of plus or minus 1% [43] Question: Progress on sales force expansion - Management expressed excitement about the sales team's performance and their ability to improve overall performance across all products [45] Question: Gating factors for the six to twelve month adoption timeframe for EXPAREL - Management highlighted that confirmation of reimbursement and the need for commercial payers to follow CMS guidelines are key factors influencing the adoption timeline [81] Question: Update on PCRX201 and recent three-year data - Management reported strong excitement around PCRX201, with positive feedback from investigators and ongoing enrollment in the ASCEND study [64]

Core Viewpoint - Pacira BioSciences reported first-quarter 2025 adjusted earnings of 62 cents per share, exceeding the Zacks Consensus Estimate of 57 cents, while total revenues of $168.9 million fell short of the expected $175 million [1][2] Financial Performance - Adjusted earnings for Q1 2025 were 62 cents per share, consistent with the same quarter last year [1] - Total revenues reached $168.9 million, a 1% increase year over year, but missed the Zacks Consensus Estimate [1] - Exparel's net product sales were $136.5 million, up 3% from the previous year, but below the consensus estimate of $140.2 million [2][4] - Zilretta's net product sales were $23.3 million, down 10% year over year, missing both the consensus and model estimates [4] - Iovera's net product sales were $5.1 million, a 2% increase year over year, but below the consensus estimate of $5.5 million [5] Expenses - Research and development (R&D) expenses (excluding stock-based compensation) increased by 41% to $23.1 million due to higher product development and clinical study costs [6] - Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) rose 19% to $76.2 million, driven by increased investments in commercial and marketing activities [7] Guidance and Projections - For 2025, Pacira BioSciences expects total revenues between $725 million and $765 million, with an adjusted gross margin projected between 76% and 78% [8] - Adjusted R&D expenses are anticipated to be between $90 million and $105 million, while adjusted SG&A expenses are expected to range from $290 million to $320 million [10] Recent Developments - The company announced the dosing of the first patient in a mid-stage study for pipeline candidate PCRX-201, aimed at treating osteoarthritis of the knee [11] - A settlement agreement with Fresenius and others regarding Exparel patents protects sales from generic competition until at least 2030 [12] - A U.S. District Court ruling eliminated the obligation to pay a low single-digit royalty on Exparel sales, expected to enhance profitability and revenue growth [13]